Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Elixiron Immunotherapeutics
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer’s Disease
June 10, 2026